

---

---

PATENT  
ATTORNEY DOCKET NO. 05032-00031

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: )  
Yvo Maria Franciscus Graus et al. ) Examiner:  
Serial No.: TBA (Cont. of USSN 09/734,389) ) Art Unit:  
Filed: Herewith )  
Title: CHLOROGENIC ACID AND AN ANALOG )  
THEREOF FOR IMMUNE SYSTEM )  
STIMULATION )

---

Commissioner for Patents  
Mail Stop Patent Application  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 C.F.R. §§ 1.97-1.99, Applicants submit the enclosed PTO form 1449. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. §1.56 and is being filed with the application.

Under 35 USC 120, this application relies on the earlier filing date of application serial number 09/734,389, filed on December 11, 2000. Hard copies of the references identified on the PTO Form 1449 were submitted to and/or cited by the Office in the prior patent application and, therefore, are not provided in this application.


In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is

intended as to the relative importance of any portion of the references. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. 102 or 103.

Please apply any charges or credits to Deposit Account No. 19-0733.

Respectfully submitted,

Dated: July 2, 2003

  
John P. Iwanicki, Reg. No. 34,628  
BANNER & WITCOFF, LTD.  
28 State Street, 28th Floor  
Boston, MA 02109  
Telephone: (617) 720-9600

USPTO Form 144 9  INFORMATION DISCLOSURE CITATION Sheet 1 of 1			U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 05032-00031		Serial No. TBA	
			Applicants: Yvo Maria Franciscus Graus et al.					
			Filing Date: Herewith				Group:	
U.S. PATENT DOCUMENTS								
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)	
	AA	2,073,616	03/16/37	Acree and Foster			07/15/27	
	AB	4,454,286	06/12/84	Daniels et al.	524	503	04/11/83	
	AC	4,950,751	08/21/90	DeWitt	536	128	06/02/89	
	AD	5,080,906	01/14/92	Carenzi et al.	424	452	07/27/90	
	AC	5,096,708	03/17/92	Gohla et al.	424	195.1	06/08/89	
	AC	5,788,971	08/04/98	Togasaki	424	195.1	10/21/93	
	AC	5,972,993	10/26/99	Ptchelintsev	514	449	03/20/98	
	AH	6,331,565	12/18/01	Dong et al.	514	532	03/01/99	
FOREIGN PATENT DOCUMENTS								
Examiner Initial		Document No.	Date	Country	Class	Subclass	Translation	
							YES	NO
	AI	CN 1179948	04/29/98	China				X
	AJ	EP 0 606 080	07/13/94	EPO				
	AK	EP 0 906 761	04/07/99	EPO				
	AL	JP 60-243016	03/12/85	Japan				X <sup>1</sup>
	AM	WO 92/13896	08/20/92	PCT				
	AN	WO 98/11778	03/26/98	PCT				
	AO	WO 99/34812	07/15/99	PCT				
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)								
	AP	Exon et al., "Effect of Dietary Chlorogenic Acid on Multiple Immune Functions and Formation of Aberrant Crypt Foci in Rats," <i>J. Toxicology and Environmental Health</i> , Part A, 53:375-384 (1998)						
	AQ	King et al., "Structure-Activity Relationships: Analogs of the Dicaffeoylquinic and Dicaffeoltartaric Acids as Potent Inhibitors of Human Immunodeficiency Virus Type 1 Integrase and Replication," <i>J. Med. Chem.</i> , 42:497-509 (1999)						
	AR	Panizzi et al., <i>Gazz. Chim. Ital.</i> , 86:913 (1956)						
	AS	Zhu et al., "Irreversible Inhibition of Human Immunodeficiency Virus Type 1 Integrase by Dicaffeoylquinic Acids," <i>J. Virology</i> , 73(4):3309-3316 (1999)						
	AT	<i>Dorland's Medical Dictionary</i> , 27 <sup>th</sup> ed. pp. 369 and 1043 (1988)						
EXAMINER					DATE CONSIDERED			
<small>*EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. **Copies of references not provided at the time of this submission.</small>								

<sup>1</sup> Abstract only